Document is current
Any future updates will be listed below
-
Authors
Brehm, Niklas
Biavasco, Francesca
Clausen, Johannes https://orcid.org/0000-0002-2729-9706
Jung, Johannes https://orcid.org/0000-0003-0137-7929
Maas-Bauer, Kristina https://orcid.org/0000-0003-1788-2807
Wäsch, Ralph https://orcid.org/0000-0002-0813-3444
Verbeek, Mareike
Nuernbergk, Christoph
Ihorst, Gabriele https://orcid.org/0000-0002-8091-1589
Seropian, Stuart
Finke, Jürgen https://orcid.org/0000-0002-1799-5927
Gowda, Lohith
Sidlik Muskatel, Rakefet
Peffault de Latour, Régis
Socie, Gérard https://orcid.org/0000-0002-2114-7533
Wehr, Claudia https://orcid.org/0000-0002-5037-6175
Michonneau, David https://orcid.org/0000-0003-4553-3065
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB-1479 – Project ID: 441891347)
Deutsche Forschungsgemeinschaft (RU5659 TARGET-MPN: ZE 872/6-1)
- License Information
-
More Information
Article History
Received: 31 January 2025
Revised: 15 March 2025
Accepted: 31 March 2025
First Online: 14 April 2025
Competing interests
: CW: received honoraria or travel support from Takeda, MSD, Jazz Pharmaceuticals and Grifols. DM: has received research grants from Novartis, CSL Behring and Sanofi, received consulting fees from Novartis, Incyte, Mallinckrodt and Sanofi, honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Jazz Pharmaceuticals. He has received support for attending meetings and/or travel from Novartis and Sanofi. He has participated in a Data Safety Monitoring Board or Advisory Board for Incyte and Sanofi. GI: none for this work. JC: received speakers fees and research funding from Novartis and Takeda. JF: none for this work. JJ: none for this work. RPL: Expert consultant / speaker: Alexion, Amgen, Apellis, Jazz, Novartis, Pfizer, Roche & Samsung - Research grant: Alexion, Novartis and Pfizer. RW: received honoraria from Abbvie, Alexion Amgen, BMS, Janssen, Kite/Gilead, Pfizer Sanofi, Takeda. RZ: received speakers fees from Incyte, Novartis, Sanofi, Medac and Mallinckrodt/Therakos. The other authors have no conflict of interest with this manuscript to disclose.
